Alykhan F Shamji

20130338092, Dec 19, 2013

Aug 16, 2013

13/969213

Benjamin L. Ebert - Brookline MA, US
Andrew M. Stern - Boston MA, US
Peter G. Miller - Boston MA, US
D. Gary Gilliland - Wellesley MA, US
Anne Van Dyk Carpenter - Ashland MA, US
David J. Logan - Maynard MA, US
Joseph Negri - Jamaica Plain MA, US
Nicola Tolliday - Jamaica Plain MA, US
Alykhan Shamji - Somerville MA, US
Siddhartha Mukherjee - New York NY, US
Alison Stewart - Cambridge MA, US

G01N 33/50
A61K 31/4184
A61K 31/395
A61K 31/428
A61K 31/423
A61K 31/704
A61K 31/4745
A61K 31/405
A61K 31/4418
A61K 31/366
A61K 31/22
A61K 31/167
A61K 31/444

514 34, 506 10, 514616, 514395, 514622, 514449, 514367, 514375, 514332, 514619, 514294, 514419, 514277, 514460, 514510

This invention relates to high-throughput, semi-automated methods for identifying compounds that are effective in targeting leukemia stem cells, as well as compounds identified by those methods and uses thereof for treating leukemia.

20220305016, Sep 29, 2022

Jan 21, 2022

17/581818

- Boston MA, US
- Cambridge MA, US
Ramnik Xavier - Brookline MA, US
Nathanael S. Gray - Stanford CA, US
Yanke Liang - Belmont MA, US
Hwan Geun Choi - Chestnut Hill MA, US
Alykhan Shamji - Somerville MA, US

The General Hospital Corporation - Boston MA
The Broad Institute, Inc. - Cambridge MA
Dana-Farber Cancer Institute, Inc. - Boston MA

A61K 31/519
A61P 19/10

The present disclosure provides methods of treating and/or preventing osteoporosis using salt-inducible kinase (SIK) inhibitors. Also provided are methods of using SIK inhibitors for increasing the function of osteocytes, increasing the number of osteoblasts, increasing the activity of osteoblasts, inhibiting the resorption of a bone, decreasing the number of osteoclasts, inhibiting the activity of osteoclasts, increasing the mass of a bone, down-regulating the expression of the gene SOST, and/or inhibiting the activity of sclerostin. The SIK inhibitors may be combined with Src inhibitors or CSF I R inhibitors. Exemplary SIK inhibitors include the compounds of the formula: (I), (II), (III), (IV), (V) or (VI).

20210147425, May 20, 2021

Nov 20, 2020

16/953984

- Cambridge MA, US
- Boston MA, US
Thomas Sundberg - Boston MA, US
Alykhan Shamji - Somerville MA, US
Ramnik Xavier - Brookline MA, US
David E. Fisher - Newton MA, US
Nisma Mujahid - Spencerport NY, US

The Broad Institute, Inc. - Cambridge MA
Dana-Farber Cancer Institute, Inc. - Boston MA
The General Hospital Corporation - Boston MA

C07D 487/04

The present disclosure provides compounds of Formula (I), (II), and (III). The provided compounds are able to bind C protein kinases (e.g., SIK) and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase (e.g., SIK, (e.g., SIK1, SIK2, or SIK3)) in a subject or cell. The provided compounds may be useful in treating or preventing a disease (e.g., proliferative disease, musculoskeletal disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.

20200317675, Oct 8, 2020

Jul 5, 2017

16/315438

- Cambridge MA, US
- Boston MA, US
Thomas SUNDBERG - Boston MA, US
Alykhan SHAMJI - Somerville MA, US
Ramnik XAVIER - Brookline MA, US
David E. FISHER - Newton MA, US
Nisma MUJAHID - Spencerport NY, US

The Broad Institute, Inc. - Cambridge MA
Dana-Farber Cancer Institute, Inc. - Boston MA
The General Hospital Corporation - Boston MA

C07D 487/04

The present disclosure provides compounds of Formula (I), (II), and (III). The provided compounds are able to bind protein kinases (e.g., SIK) and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase (e.g., SIK, (e.g., SIK1, SIK2, or SIK3)) in a subject or cell. The provided compounds may be useful in treating or preventing a disease (e.g., proliferative disease, musculoskeletal disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.

20200268736, Aug 27, 2020

Sep 26, 2018

16/651163

Elizaveta Leshchiner - Cambridge MA, US
Zhifang Cao - Cambridge MA, US
Jason Rush - Cambridge MA, US
Michael Durney - Cambridge MA, US
Alykhan Shamji - Cambridge MA, US
Daniel Graham - Cambridge MA, US
Stuart L. Schreiber - Cambridge MA, US
Ramnik Xavier - Cambridge MA, US

A61K 31/4545
A61K 31/496

Disclosed herein are compounds for the treatment of inflammatory bowel disease. Additionally, provided herein are compositions and methods for using these compounds and compositions in the treatment of inflammatory bowel disease in a subject.

20200179387, Jun 11, 2020

Sep 16, 2017

16/333546

- Boston MA, US
- Cambridge MA, US
Ramnik Xavier - Brookline MA, US
Nathanael S. Gray - Boston MA, US
Yanke Liang - Belmont MA, US
Hwan Geun Choi - Chestnut Hill MA, US
Alykhan Shamji - Somerville MA, US

The General Hospital Corporation - Boston MA
The Broad Institute, Inc. - Cambridge MA
Dana-Farber Cancer Institute, Inc. - Boston MA

A61K 31/519
A61P 19/10

The present disclosure provides methods of treating and/or preventing osteoporosis using salt-inducible kinase (SIK) inhibitors. Also provided are methods of using SIK inhibitors for increasing the function of osteocytes, increasing the number of osteoblasts, increasing the activity of osteoblasts, inhibiting the resorption of a bone, decreasing the number of osteoclasts, inhibiting the activity of osteoclasts, increasing the mass of a bone, down-regulating the expression of the gene SOST, and/or inhibiting the activity of sclerostin. The SIK inhibitors may be combined with Src inhibitors or CSF I R inhibitors. Exemplary SIK inhibitors include the compounds of the formula: (I), (II), (III), (IV), (V) or (VI).

20160102087, Apr 14, 2016

Aug 4, 2015

14/818009

- Cambridge MA, US
Jason Law - Cambridge MA, US
Matthias Leiendecker - Trier, DE
Ke Liu - Cambridge MA, US
Benito Munoz - Newtonville MA, US
Stuart Schreiber - Boston MA, US
Alykhan Shamji - Somerville MA, US
Andrew Stern - Boston MA, US

C07D 419/12
C07D 413/14
C07D 498/04
C07D 413/12
C07D 417/14

The invention relates to compounds of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof:

20140100223, Apr 10, 2014

Sep 26, 2013

14/037761

- Cambridge MA, US
Jason Law - Cambridge MA, US
Matthias Leiendecker - Trier, DE
Ke Liu - Cambridge MA, US
Benito Munoz - Newtonville MA, US
Stuart Schreiber - Boston MA, US
Alykhan Shamji - Somerville MA, US
Andrew Stern - Boston MA, US

PRESIDENT & FELLOWS OF HARVARD COLLEGE - Cambridge MA
THE BROAD INSTITUTE, INC. - Cambridge MA

C07D 419/12
C07D 413/14
C07D 498/04
C07D 413/12
C07D 417/14

5142338, 540468, 514338, 514256, 514333, 514318, 514314, 514397

The invention relates to compounds of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof: